Emergent BioSolutions (NYSE: EBS) announced it has received a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response, part of the U.S. Department of Health and Human Services, to supply its ACAM2000 smallpox and mpox vaccine.

The contract covers the vaccine itself, ancillary supplies, and diluent replacement lots for smallpox preparedness and response. Deliveries are expected to begin in June 2026. The modification falls under Emergent's existing 10-year contract with ASPR.

The announcement follows recent regulatory approvals for ACAM2000 in other markets. Saudi Arabia's Food and Drug Authority approved the vaccine for immunization against smallpox and mpox in high-risk individuals, and Singapore's Health Sciences Authority approved an expanded indication to include prevention of mpox in adults at high risk of infection.

ACAM2000 is indicated for active immunization to prevent smallpox and mpox disease in individuals determined to be at high risk for infection. The vaccine carries a boxed warning for serious complications, including myocarditis, pericarditis, encephalitis, and other conditions. It is contraindicated in individuals with severe immunodeficiency.

Information in this article is based on a press release statement from Emergent BioSolutions.